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The potent anti-inflammatory agents, glucocorticoids (GCs) are frequently used for the
treatment of inflammatory diseases such as arthritis, pulmonary diseases, and skin
diseases. It is well known that high-dose or long-term use of GCs results in several adverse
side effects including osteoporosis.
1 Epidemiological studies have demonstrated the high
incidence of fractures at the spine (the skeletal site rich in trabecular bone), followed by
fractures at the hip (the skeletal site rich in both trabecular and cortical bone).
2 This is
probably because GC-induced osteoporosis is more evident in trabecular bone than in
cortical bone.
3 Thus, the primary strategy for GC-induced osteoporosis seems to be the
prevention of vertebral fractures.
Both vitamin K2 and risedronate are widely used in the treatment of GC-induced
osteoporosis in Japan,
4 because both drugs have been reported to be effective in reducing
incidence of vertebral fractures.
5-7 Risedronate decreases bone turnover, increases bone
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treated with GCs.
5,6 An iliac biopsy study clearly demonstrated
that risedronate prevented the deterioration of trabecular bone
architecture, reduced the degree of mineralization, and preserved
elastic modulus within the trabeculae in patients treated with
GCs.
8 However, there are no data to show the effect of vitamin
K2 on bone formation and resorption and trabecular bone in
patients treated with GCs.
Several preclinical studies using GC-treated rats have demon-
strated that risedronate suppresses bone turnover and increases
trabecular bone mass,
9 while vitamin K2 attenuates reductions
in periosteal bone formation and cortical bone mass as well as
trabecular bone mass evaluated by micro computed tomogra-
phic analysis.
10 However, the effects of vitamin K2 on bone
mass and bone formation and resorption in trabecular bone
remain uncertain. The purpose of the present study was to
compare the effect of vitamin K2 and risedronate on trabecular
bone in GC-treated rats.
Treatment of animals
Fifty Sprague-Dawley female rats, 3 months of age, were
purchased from Hilltop Lab. Animals, Inc. (Scottdale, PA, USA).
The animals were housed under local vivarium conditions
(temperature 23.8˚C and 12-h on/off light cycle), and were fed a
pelleted standard chow diet containing 1.36% calcium and 2,400
IU/kg vitamin D (Rodent Diet 8604, Harlan Teklad, Madison,
WI, USA), with free access to water. Following a 1-week
adaptation to the new environment, the rats were randomized by
the stratified weight method into 5 groups of 10 rats each
according to the following treatment schedule: age-matched
control, CG administration, and GC administration with
concomitant administration of vitamin K2, risedronate, or vitamin
K2 + risedronate. Five-hundred mg of methylprednisolone
sodium succinate (Pharmacia & Upjohn Company, Kalamazoo,
MI, USA) was reconstituted with 15 mL of bacteriostatic water
and then subcutaneously administered as the GC at a dose of 5.0
mg/kg body weight three times a week. Vitamin K2 (menate-
trenone, Eisai Co., Ltd., Tokyo, Japan) was suspended in 0.1 mL
of 1,2-propanediol and glycerol solution at a dosage of 30 mg/kg
body weight and administered by gavage into deep mouth three
times a week. Risedronate (Eisai Co., Ltd., Tokyo, Japan) was
dissolved in 0.1 mL of PBS solution at a dosage of 10 µg/kg
body weight, and then subcutaneously administered 5 times a
week. The doses of vitamin K2 and risedronate were considered to
be effective in rats, in accordance with previously published
data.
9,11,12 Two rats in the GC + vitamin K2 + risedronate group
were deleted from the study because of a failure of GC injections
during the experiment in 1 rat and a failure of making bone
sections for bone histomorphometry in the other. The body weight
of the rats was monitored weekly, and the total experimental
period was 8 weeks. The study was carried out at Winthrop-
University Hospital, and the animals were maintained according
to the National Institutes of Health (NIH) Guidelines for Care
and Use of Laboratory Animals. All animal experimental
protocols were approved by the Laboratory Animal Care
Committee of Winthrop-University Hospital.
Preparation of specimens
All the rats were labeled with 10 mg/kg of calcein (Sigma
Chemical, St. Louis, MO, USA) injected intramuscularly 10
days and 3 days before they were sacrificed. The animals were
anesthetized with intraperitoneally injected ketamine at 80
mg/kg, together with xylazine at 12 mg/kg, and sacrificed by
exsanguination. The left femur and right tibia were collected
from every animal. The femurs were stored in a freezer (-70˚C)
and processed later for the measurements of the femoral length
and bone mineral density (BMD) as described below. The right
tibiae were used for bone histomorphometric analysis of the
tibial proximal metaphysis; the bones were fixed overnight in
40% cold ethanol, and then cut into three parts using an Isomet
saw (Buehler, Lake Bluff, IL, USA). The proximal tibial
metaphyses were stained with Villanueva Osteochrome Bone
Stain (Polyscience, Warrington, PA, USA) for 5 days. The
specimens were then dehydrated sequentially in ascending
concentrations of ethanol (70%, 95%, and 100%) and xylene
and then embedded in methyl methacrylate (EM Science,
Gibbstown, NJ, USA) at 4˚C, in accordance with the method of
Erben.
13 Frontal sections of the proximal tibial metaphysis were
cut at 5-µm thickness using a microtome (Leica RM2155;
Leica Inc., Nussloch, Germany), transferred onto chromium-
gelatin-coated slides, dried overnight under pressure at 42˚C,
and coverslipped with Eukitt mounting medium (Calibrated
Instruments, Hawthorne, NY, USA) for static and dynamic
histomorphometric analyses.
Bone histomorphometric analysis of the tibial proximal
metaphysis
A digitizing morphometric system was used to measure bone
histomorphometric parameters. The system consisted of an
epifluorescence microscope (Nikon E-400, OsteoMetrics,
Atlanta, GA, USA), an Osteomeasure High Resolution Color
Subsystem (OsteoMetrics, Atlanta, GA, USA) coupled to an
IBM computer, and a morphometry program (OsteoMetrics,
Atlanta, GA, USA). The parameters measured for trabecular
bone included total tissue volume (TV), bone volume (BV),
bone surface (BS), eroded surface (ES), single- and double-
labeled surfaces (sLS and dLS, respectively), and interlabel
width. These data were used to calculate percent trabecular
bone volume (BV/TV), trabecular number (Tb N), trabecular
thickness (Tb Th), trabecular separation (Tb Sp), ES/BS,
mineralizing surface (MS)/BS [(sLS/2+dLS)/BS], mineral
apposition rate (MAR), bone formation rate (BFR)/BS, and
BFR/BV, in accordance with the standard nomenclature
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MATERIALS AND METHODSproposed by Parfitt et al.
14 In the present study, the region of
trabecular bone measured was 1-4 mm distal to the lower margin
of the growth plate in the proximal tibial metaphysis, which
consists of secondary spongiosa. In addition to measurement of
the above parameters, interlabel width beneath the growth plate
was used to calculate longitudinal growth rate (LGR).
Measurements of femoral length and BMD
The length of the whole left femur was measured with a dial
caliper. The BMD of the whole left femur was determined by
dual energy X-ray absorptiometry (DXA) using a Hologic QDR-
4500 Plus (Hologic Inc., Bedford, MA, USA). The instrument
was adapted for an ultra-resolution mode, with line spacing of
0.0254 cm, resolution of 0.0127 cm, and collimation of 0.9 cm
diameter. The bone was placed in a Petri dish, and to simulate
soft-tissue density, tap water was poured around the bone to a
depth of 1 cm. The bone mineral content and bone area were
measured, and the BMD of that area was calculated by dividing
bone mineral content by bone area. The coefficient of variation of
these measurements at our laboratory was less than 1.0%.
15
Statistical analysis
All the data were expressed as means and standard deviation
(SD). Mann-Whitney U-test was used to compare the data
between the age-matched control group and other groups. Two-
way factorial analysis of variance (ANOVA) was used to
examine the effect of vitamin K2 and risedronate and their
combination effect, using the data from the GC, GC + vitamin
K2, GC + risedronate, and GC + vitamin K2 + risedronate groups.
All statistical analyses were performed using the Stat View J-
5.0 program on a Macintosh computer. A significance level of
p< 0.05 was used for all the comparisons.
Effect of GC administration
GC induced reductions in body weight and femoral BMD
Vitamin K2 and Risedronate in GC-Treated Rats
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Table 1.Initial and Final Body Weight and Femoral Length and Bone Mineral Density
Initial body weight Final body weight Femoral length Femoral BMD   
(g) (g) (mm) (mg/cm
2)
Age-matched control 287 ± 13 307 ± 15 35.7  ± 0.6 277 ± 9
GC 281 ± 8 273 ± 11* 35.1 ± 0.8 263 ± 9
�
GC + vitamin K2 290 ± 6 291 ± 16
� 35.3 ± 0.5 265 ± 8
�
GC + risedronate 291 ± 8 294 ± 10
� 35.5 ± 0.6 274 ± 9
GC + vitamin K2 + risedronate 290 ± 9 289 ± 11
� 35.4 ± 0.6 275 ± 8
Effect of vitamin K2 NS NS NS
Effect of risedronate < 0.05 NS < 0.001
Effect of vitamin K2 + risedronate NS NS NS
GC, glucocorticoid; BMD, bone mineral density; NS, not significant.
*p< 0.0001, 
�p < 0.01, 
�p < 0.05 vs. the age-matched control group.
Data are expressed as mean ± SD. Mann Whitney U-test was used to compare the data between the age-matched control group and
other groups. Two-way factorial analysis of variance (ANOVA) was used to determine the effect of vitamin K2and risedronate and their
combination effect. 
Table 2. Bone Histomorphometric Analysis of Cancellous Bone of the Proximal Tibial Metaphysis-Structural 
Parameters- 
BV/TV (%) Tb N (#/mm) Tb Th (µm) Tb Sp (µm)  
Age-matched control 27.2 ± 4.6 4.5 ± 0.7 60.6 ± 6.1 239 ± 46
GC 20.5 ± 3.1* 3.8 ± 0.6
� 54.6 ± 5.1
� 312 ± 66
�
GC + vitamin K2 23.0 ± 2.8
� 4.2 ± 0.5 54.6 ± 4.9 266 ± 39
GC + risedronate 26.4 ± 2.6 4.0 ± 0.7 66.7 ± 10.5 271 ± 63
GC + vitamin K2 + risedronate 28.0 ± 3.4 4.2 ± 0.5 67.2 ± 9.4 250 ± 37
Effect of vitamin K2 < 0.05 NS NS NS
Effect of risedronate < 0.0001 NS < 0.0001 NS
Effect of vitamin K2 + risedronate NS NS NS NS
GC, glucocorticoid; BV, bone volume; TV, total tissue volume; Tb N, trabecular number; Tb Th, trabecular thickness; Tb Sp, trabecular 
separation; NS, not significant.
*p < 0.01, 
�p < 0.05 vs. the age-matched control group.
Data are expressed as mean ± SD. mann Whitney U-test was used to compare the data between the age-matched control group and
other groups. Two-way factorial analysis of variance (ANOVA) was used to determine the effect of vitamin K2and risedronate and their
combination effect. 
RESULTS(Table 1). GC also induced reductions in trabecular BV/TV, Tb
N and Tb Th and increase in Tb Sp (Table 2), as a result of
decreased bone formation (MS/BS, MAR, BFR/BS, BFR/BV)
and increased bone erosion (ES/BS) (Table 3). GC reduced
LGR/day (Table 3), but did not affect femoral length (Table 1).
Effect of vitamin K2 administration on GC-treated rats
Vitamin K2 did not affect body weight and femoral BMD
(Table 1). However, vitamin K2 attenuated GC-induced
reduction in trabecular BV/TV (Table 2) by preventing GC-
induced decrease in bone formation (MS/BS) and subsequently
reducing GC-induced increase in bone erosion (ES/BS) (Table
3). Vitamin K2 did not affect either LGR/day (Table 3) or
femoral length (Table 1).
Effect of risedronate administration on GC-treated rats
Risedronate attenuated GC-induced reduction in body weight
and prevented GC-induced reduction in femoral BMD (Table
1). Risedronate also prevented GC-induced reductions in
trabecular BV/TV and Tb Th (Table 2) by preventing GC-
induced increase in bone erosion (ES/BS) although it also
suppressed bone formation (MS/BS, MAR, BFR/BS, BFR/BV)
(Table 3). Risedronate did not affect either LGR/day (Table 3)
or femoral length (Table 1).
Effect of combined administration of vitamin K2 and
risedronate on GC-treated rats
There was no combination effect of vitamin K2 and risedronate
on body weight and femoral length and BMD (Table 1) as well
as trabecular bone structural parameters (Table 2). However,
vitamin K2 mildly attenuated the suppression of bone formation
(MS/BS) and bone erosion (ES/BS) caused by risedronate
when administered in combination (Table 3).
Images of the proximal tibial metaphysis
Fig. 1 shows the images of the proximal tibial metaphysis,
confirming the results of bone histomorphometric analysis
regarding trabecular BV/TV.
The present study found the differential effect of vitamin K2
and risedronate on trabecular bone in GC-treated rats. Vitamin
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Table 3.Bone Histomorphometric Analysis of Cancellous Bone of the Proximal Tibial Metaphysis - Formative and Resorptive Parameters 
LGR/day MS/BS MAR BFR/BS BFR/BV ES/BS 
(µm/day) (%) (µm/day) (µm
3/µm
2/day) (%/yr) (%)
Age-matched control 9.6 ± 0.8 16.4 ± 5.3 1.11  ± 0.14 18.6 ± 7.8 189  ± 83 2.78 ± 1.23
GC 8.5 ± 1.1
� 8.7 ± 4.7
� 0.86 ± 0.16
� 7.7 ± 4.9
� 87 ± 55
� 6.73 ± 2.60
�
GC + vitamin K2 9.1 ± 1.3 12.6 ± 3.8 0.86  ± 0.15
� 10.9 ± 3.8
� 120 ± 37
� 4.18 ± 2.13
�
GC + risedronate 8.2 ± 1.3
� 2.2 ± 0.5* 0.67 ± 0.15* 1.4 ± 0.4* 13 ± 4* 1.83 ± 0.87
GC + vitamin K2 + risedronate 8.7 ± 1.0
� 2.8 ± 0.9* 0.70 ± 0.17* 2.0 ± 1.0* 18 ± 8* 2.11 ± 0.73
Effect of vitamin K2 NS < 0.05 NS NS NS < 0.05
Effect of risedronate NS < 0.0001 < 0.01 < 0.0001 < 0.0001 < 0.0001
Effect of vitamin K2 + risedronate NS < 0.05 NS NS NS < 0.05
GC, glucocorticoid; LGR, longitudinal growth rate; MS, mineralizing surface; BS, bone surface; MAR, mineral apposition rate; BFR, bone formation rate; BV, bone 
volume; ES, eroded surface; NS, not significant.
* p < 0.001, 
�p < 0.01, 
�p < 0.05 vs. the age-matched control group.
Data are expressed as mean ± SD. Mann Whitney U-test was used to compare the data between the age-matched control group and other groups. Two-way
factorial analysis of variance (ANOVA) was used to determine the effect of vitamin K2and risedronate and their combination effect.  
DISCUSSION
Fig. 1. Images of the proximal tibial metaphysis. The images of the proximal tibial metaphysis confirm the results of bone histomorphometric analysis regarding trabecular
BV/TV. GC, glucocorticoid; BV, bone volume; TV, total tissue volume.
Age-matched control GC GC + Vitamin K2 GC +  risedronate GC + Vitamin K2 + risedronateK2 attenuated GC-induced trabecular bone loss by preventing
GC-induced decrease in bone formation (MS/BS) and
subsequently reducing GC-induced increase in bone erosion
(ES/BS). Risedronate prevented GC-induced trabecular bone
loss by preventing GC-induced increase in bone erosion
(ES/BS) although it also suppressed bone formation (MS/BS,
MAR, BFR/BS, BFR/BV). Vitamin K2 mildly attenuated
suppression of bone formation (MS/BS) and bone erosion
(ES/BS) caused by risedronate without affecting trabecular
bone mass when administered in combination.
It has been argued that rat is a poor model of GC-induced
osteoporosis, because GC inhibits bone resorption by
osteoclasts, resulting in a protective effect on the skeleton in
mature rats
16. However, GC administration has been shown to
induce losses of trabecular BV/TV, Tb N, and Tb Th in young
rats
10,17-20. Therefore, the clearly observed trabecular bone loss in
GC-treated young rats in the previous studies could be due, at
least in part, to growth inhibition. However, GC treatment is
required even in children with nephritis, systemic lupus
erythematosus, asthma, juvenile idiopathic or rheumatic
arthritis, lymphoblastic leukemia, and other diseases. Therefore,
it is important to study the effects of drugs on GC-induced bone
loss in young rats. In the present study, GC administration
induced trabecular bone loss in young rats compared with age-
matched controls.
GC-induced trabecular bone loss has been associated with
decreased bone formation and increased bone resorption,
however the key histological feature of GC-induced trabecular
bone loss has been shown to be reduction in the thickness of
trabecular bone, reflecting suppressed bone formation
21. In the
present study, GC-induced trabecular BV/TV loss compared
with age-matched controls was associated with decreases in Tb
Th and Tb N and increase in Tb Sp because bone formation
was decreased and bone erosion was increased by GC
administration. Because bone erosion reflects the coupling of
bone formation to bone resorption, both decreased bone
formation and increased bone resorption could account for
increased bone erosion.
Vitamin K2 is known to have an anabolic action on bone;
regulation of bone formation by vitamin K2 may involve γ-
carboxylation of osteocalcin and/or may be mediated by the
steroid and xenobiotic receptor.
22-26 In the present study, vitamin
K2 attenuated GC-induced trabecular bone loss by preventing
GC-induced decrease in bone formation (MS/BS) and subse-
quently reducing GC-induced increase in bone erosion. These
results suggest at least the mild anabolic effect of vitamin K2,
because bone erosion reflects the coupling of bone formation to
bone resorption. However, the effects of vitamin K2 on trabecu-
lar bone mass and bone metabolism seem to be modest.
The bisphosphonates inhibit osteoclast-mediated bone
resorption, and loss of osteoclast function and apoptosis are the
consequence of loss of function of one or more important
signaling proteins. In particular, nitrogen-containing bisphos-
phonates, such as alendronate and risedronate, are not
metabolized but can inhibit enzymes of the mevalonate
pathway, thereby preventing the biosynthesis of isoprenoid
compounds, which are essential for the post-translational
modification of small GTPases.
27 In the present study,
risedronate prevented GC-induced trabecular bone loss by
preventing GC-induced increase in bone erosion although it
also suppressed bone formation (mineralizing surface, mineral
apposition rate, and bone formation rate). Thus, risedronate
ameliorated the imbalance of bone formation and resorption.
These results are consistent with those of previous studies.
9
However, oversuppression of bone formation as well as bone
resorption is concerned.
Because vitamin K2 and risedronate have different actions on
bone formation and resorption, the beneficial effects of combi-
nation of the 2 agents on trabecular bone could be expected. A
few studies showed the effects of combined treatment with
bisphosphonates and vitamin K2 in other models of osteo-
porosis.
28-31 Ito et al.
29 demonstrated additive effect of risedronate
and vitamin K2 in preventing deterioration of the trabecular
bone architecture in ovariectomized rats, whereas Otomo et al.
30
showed no significant additive effect of risedronate and vitamin
K2 on bone turnover, bone mass/density, bone structure,
mineral properties (mineral-to-matrix ratio), and bone strength
evidenced by no significant effect of vitamin K2 on bone
parameters in ovariectomized rats. Furthermore, Iwasaki et al.
31
reported that concomitant use of vitamin K2 with incadronate
ameliorated suppression of bone formation and more effecti-
vely prevented cancellous bone loss in tail-suspended rats. In
the present study, risedronate strongly suppressed bone
formation and erosion, and vitamin K2 mildly attenuated the
suppression of bone formation (MS/BS) and bone erosion
caused by risedronate without affecting trabecular bone mass
when administered in combination. Bone strength reflects both
bone mass and bone quality, and bone quality is determined by
the bone architecture, turnover, damage accumulation, minera-
lization, and matrix.
32 Thus, strong suppression of bone
formation as well as bone resorption caused by risedronate
might possibly lead to deterioration of bone quality. Vitamin K2
might have a mild anabolic effect, possibly playing a role in
attenuating deterioration of bone quality in rats treated with GC
and risedronate.
In conclusion, the present study showed differential effects of
vitamin K2 and risedronate on trabecular bone in GC-treated
rats. Vitamin K2 attenuated GC-induced trabecular bone loss
via a mild anabolic effect. Risedronate prevented GC-induced
trabecular bone loss via a strong antiresorptive effect. These
results suggest that risedronate should be a first line drug, while
vitamin K2 remains to be a second line drug in preventing
vertebral fractures in patients treated with GCs. Vitamin K2
might play a role in improving bone turnover possibly coun-
teracting by risedronate-induced oversuppression of bone
turnover when administered in combination.
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